Mumbai: Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...

The research suggests that liraglutide, a drug originally developed for diabetes (Victoza) and weight management (Saxenda), may significantly reduce the frequency of debilitating migraine.

Lupin receives USFDA approval for generic diabetes medications, including Liraglutide Injection and Glucagon for Injection.

A new study found that GLP-1 weight-loss drugs with the active ingredient liraglutide can significantly reduce migraines.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...

The liraglutide group also showed greater improvements in glycated hemoglobin level, plasma glucose level, and other measures of glucose control. Furthermore, ...